ProQR Therapeutics (PRQR) Non-Current Deferred Tax Liability (2020 - 2026)

ProQR Therapeutics has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $3.0 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 4.8% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (down 4.8% YoY) and the FY2025 annual result came in at $3.0 million, down 4.8% from the prior year.
• Non-Current Deferred Tax Liability slipped to $3.0 million in Q4 2025 per PRQR's latest filing, from $3.2 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $4.0 million in Q4 2023 and troughed at $3.0 million in Q4 2025.
• A 4-year average of $3.5 million and a median of $3.5 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability increased 5.74% in 2023, then retreated 21.81% in 2024.
• Over 4 years, Non-Current Deferred Tax Liability stood at $3.8 million in 2022, then advanced by 5.74% to $4.0 million in 2023, then declined by 21.81% to $3.2 million in 2024, then fell by 4.8% to $3.0 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.0 million, $3.2 million, and $4.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.